-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TX-000045 in Cardiovascular Disease
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TX-000045 in Cardiovascular Disease Drug Details: TX-000045 is under development for the treatment of cardiovascular...
-
Company Insights
Innovation and Patenting activity of TX Group AG Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of TX Group AG Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
Diastolic Heart Failure – Drugs In Development, 2023
Global Markets Direct’s, ‘Diastolic Heart Failure - Drugs In Development, 2023’, provides an overview of the Diastolic Heart Failure pipeline landscape. The report provides comprehensive information on the therapeutics under development for Diastolic Heart Failure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Drugs In Development, 2023’, provides an overview of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the...
-
Product Insights
Occlusive Arterial Disease (OAD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Occlusive Arterial Disease (OAD) - Drugs In Development, 2023’, provides an overview of the Occlusive Arterial Disease (OAD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Occlusive Arterial Disease (OAD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Peripheral Artery Occlusive Disease (PAOD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Peripheral Artery Occlusive Disease (PAOD) - Drugs In Development, 2023’, provides an overview of the Peripheral Artery Occlusive Disease (PAOD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Peripheral Artery Occlusive Disease (PAOD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Food Allergy – Drugs In Development, 2023
Global Markets Direct’s, ‘Food Allergy - Drugs In Development, 2023’, provides an overview of the Food Allergy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Food Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Non Alcoholic Fatty Liver Disease (NAFLD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Non Alcoholic Fatty Liver Disease (NAFLD) - Drugs In Development, 2023’, provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Sector Analysis
United States Confectionery Market Assessment by Categories, Distribution, Packaging, Consumergraphics and Forecasts to 2027
United States Confectionery Market Report Overview The United States (US) confectionery market was estimated to grow at $44.2 billion in 2022. The market is likely to grow at a CAGR of more than 3% during 2022-2027. The US confectionery market research report provides insights on high-growth markets to target, category-level distribution data, and companies' market shares. US Confectionery Market Outlook 2022-2027 ($ Billion) Buy the Full Report for the US Confectionery Market Forecasts, Download a Free Sample Report Market Size...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ATX-304 in Type 2 Diabetes
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATX-304 in Type 2 Diabetes report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ATX-304 in Type 2 Diabetes Drug Details: ATX-304 is under development...